Praxis Precision Medicines (PRAX) CEO gets RSUs, options grant detailed

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. Chief Executive Officer and director Marcio Souza reported new equity awards and related share activity. On January 8, 2026, he was awarded 27,640 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on January 8, 2026. That same day, he received a stock option for 22,110 shares of common stock at an exercise price of $294.38, vesting 25% on January 8, 2027 and the remaining 75% in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 4,252 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations on previously reported RSU vesting. After these transactions, he directly beneficially owned 76,890 shares of common stock, 22,110 stock options, and indirectly held 2,600 shares through his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Souza Marcio

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A(1)		27,640	A	$0	81,142	D
Common Stock	01/10/2026		F(2)		4,252	D	$288.45	76,890	D
Common Stock								2,600	I	Held by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$294.38	01/08/2026		A		22,110		(3)	01/08/2036	Common Stock	22,110	$0	22,110	D

Explanation of Responses:

1. Mr. Souza was awarded 27,640 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

3. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did PRAX CEO Marcio Souza report on this Form 4?

The filing reports 27,640 restricted stock units and a stock option for 22,110 shares of Praxis Precision Medicines common stock granted to CEO Marcio Souza on January 8, 2026, plus tax-related share withholding on January 10, 2026.

How do Marcio Souzab4s new restricted stock units in PRAX vest?

The 27,640 restricted stock units vest in equal annual installments over four years, beginning on the one-year anniversary of the vesting commencement date of January 8, 2026.

What are the terms of the new stock option granted to PRAX CEO Marcio Souza?

The stock option covers 22,110 shares of common stock at an exercise price of $294.38 per share. It vests over four years, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service.

Why were 4,252 PRAX shares withheld in this Form 4 filing?

The 4,252 shares of common stock, shown with code F at a price of $288.45, were withheld by the issuer to satisfy tax withholding obligations related to vesting of previously reported restricted stock units.

How many PRAX shares does Marcio Souza own after these transactions?

After the reported transactions, Marcio Souza directly beneficially owned 76,890 shares of Praxis Precision Medicines common stock, held 22,110 stock options, and indirectly held 2,600 shares through his spouse.

Are any of Marcio Souzab4s PRAX shares held indirectly?

Yes. The filing notes 2,600 shares of common stock are held indirectly, described as "Held by spouse", in addition to his directly held shares and options.